CEO Hedrick Buys Shares as Cerenome Rebrands to CNS Oncology
Marc H. Hedrick’s July 1 RSU vesting boosts Cerenome’s CEO stake, reinforcing confidence in its CNS‑oncology pivot and REYOBIQ milestones.
5 minutes to read
PLUS THERAPEUTICS INC
Plus Therapeutics Insider Moves: CFO Buys, CEO Sells Amid Clinical Anticipation
Plus Therapeutics insider moves: CFO buys, CEO sells; static hold by the development chief. Discover what the next clinical data release could mean for stock volatility and investor confidence.
3 minutes to read
Plus Therapeutics CEO’s RSU Gains & Stock Sales Highlight Insider Confidence and Strategic Liquidity
Plus Therapeutics insider trades reveal CEO’s long‑term commitment via RSUs while selling shares for liquidity—analyzing how this balance impacts investor confidence and the company’s biopharma pipeline.
3 minutes to read
Plus Therapeutics CFO Buys RSUs & Options Amid CPT‑Code Expansion & Market Upside
Plus Therapeutics CFO’s insider buy of RSUs and options signals bullish confidence in the company’s CPT‑code expansion and future revenue growth.
4 minutes to read